MDT-AP-1353
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 98.03999999999999
- os_event
- false
- age_years
- 2.3
- sex
- M
- new_clusters
- C3
- umap1_2d
- 4.944130356
- umap2_2d
- 0.772759111
- umap1_3d
- 1.50188873
- umap2_3d
- -3.623394501
- umap3_3d
- -1.673141129
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.370
- DNA_REPAIR+0.340
- MYC_TARGETS_V1+0.340
- MYC_TARGETS_V2+0.330
- MITOTIC_SPINDLE+0.310
- TGF_BETA_SIGNALING+0.250
- UNFOLDED_PROTEIN_RESPONSE+0.250
- G2M_CHECKPOINT+0.210
- E2F_TARGETS+0.200
- MTORC1_SIGNALING+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- ALLOGRAFT_REJECTION-0.470
- INFLAMMATORY_RESPONSE-0.470
- COAGULATION-0.460
- COMPLEMENT-0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- ANGIOGENESIS-0.360
- IL6_JAK_STAT3_SIGNALING-0.350
- KRAS_SIGNALING_DN-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR26320097 | — | — | 0.903 |
| 2 | MDT-AP-0211 | Med | Medulloblastoma | 0.901 |
| 3 | SRR1797243 | — | cohortSC | 0.899 |
| 4 | SRR26320084 | — | — | 0.896 |
| 5 | SRR8943005 | — | — | 0.895 |
| 6 | TCGA-GC-A4ZW-01A-11R-A26T-07 | — | — | 0.891 |
| 7 | R224 | — | — | 0.887 |
| 8 | 5ab66d03-c324-4ec2-b3bb-7970c121a7f5 | — | — | 0.886 |
| 9 | MDT-AP-3088 | Med | Medulloblastoma | 0.879 |
| 10 | 004064de-0e10-491d-b3d8-bc628a8f70a8 | — | — | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.210 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.070 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |